Tumor Immunology & Immunotherapy Group
Our mission is to develop novel immunotherapies for cancer. Our research focuses on understanding the mechanisms that contribute to an immune suppressive tumor microenvironment (TME) in treatment resistant cancers biased by sex immune dimorphism and utilizing targeted therapies to reshape the immune regulatory TME. We also investigate innate immune memory mechanisms to equip Natural killer cells (NK cells) with immune memory features against solid tumors.
Menu for this area
Research line I: Studies of sexual immune dimorphism in the TM
The Tumor Immunology & Immunotherapy Group aim to fill the knowledge gap about differences in sex-specific immune responses and how these contribute to the response to immunotherapy.
Research line II: aNK cells in solid tumors
The Tumor Immunology & Immunotherapy Group's exploration of a new subset of NK cells so called adaptive NK cells (aNK cells) in solid tumors.
Funding and career opportunities
Funding for Tumor Immunology & Immunotherapy Group at the Department of Laboratory Medicine.
News
Photo: Getty Images Immune cell gives possible explanation for sex differences in pancreatic cancer
Immunotherapy for pancreatic cancer has limited effect and differs between men and women. KI researchers have now found a possible explanation for this sex difference.
Differences in tumor microenvironment between female and male patients with pancreatic cancer
Dhifaf Sarhan, PhD, Karolinska Institute, Stockholm, Sweden, discusses the differences in the tumor microenvironment between female and male patients with pancreatic cancer at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Research uncovers a possible explanation for sex differences in pancreatic cancer
Immunotherapy is an effective form of therapy for different types of cancer, but for pancreatic cancer, its effect is limited and differs between men and women. Researchers at Karolinska Institutet have now found a possible explanation for this sex difference.